期刊
EXPERIMENTAL GERONTOLOGY
卷 57, 期 -, 页码 181-187出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.exger.2014.05.015
关键词
Resveratrol; Safety; Metabolism; Glucose; Blood pressure
资金
- University of Florida's McKnight Brain Institute
- Claude D. Pepper Older Americans Independence Center [NIH/NIA P30AG028740]
- Clinical and Translational Science Institute [NIH/NCRR UL1TR000064]
- American Heart Association [09CRP2390173]
- Thomas H. Maren Foundation
- [K23 AT004251-01A2]
Resveratrol has been found to have potent antioxidant, anti-inflammatory, and anticarcinogenic effects. The safety and efficacy of resveratrol supplementation in older adults are currently unknown. We conducted a double-blind, randomized, placebo-controlled trial to examine the safety and metabolic outcomes in 32 overweight, older adults (mean age, 73 +/- 7 years). Participants were randomized into one of three treatment groups: (1) placebo, (2) moderate dose resveratrol (300 mg/day), and (3) high dose resveratrol (1000 mg/day). Both resveratrol and placebo were orally ingested in capsule form twice daily for 90 days. Blood chemistry values remained within the normal range, and there were no significant differences in the number of participants reporting adverse events across conditions. Compared to placebo, glucose levels were significantly lower at post-treatment among participants randomized to both resveratrol conditions, with and without adjustment for the corresponding baseline values (ps < 0.05). Glucose values of participants in the treatment groups, however, were not significantly different from baseline levels. These findings suggest that short-term resveratrol supplementation at doses of 300 mg/day and 1000 mg/day does not adversely affect blood chemistries and is well tolerated in overweight, older individuals. These findings support the study of resveratrol for improving cardio-metabolic health in older adults in larger clinical trials. (C) 2014 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据